SORRENTO THERAPEUTICS INC

Watch

Share

SRNE·83587F202·US·Common Stock·Healthcare - Biotechnology

SRNE (SORRENTO THERAPEUTICS INC) is held by 2 institutional investors as of Q2 2026. Largest holders: HUNTINGTON NATIONAL BANK ($4), First Command Advisory Services, Inc. ($0).

2

Holders

$4

Total Value

100%

Consensus

13F: Jun 30, 2026Insider & Congress: Updated regularly

Smart Money Verdict

View all

Loading verdict

Institutional (13F)41

Insider (Form 4)62

Activist (13D/13G)85

Congressional (STOCK Act)28

Holder Quality

67

★★★★★

Elite

27

★★★★

Strong

75

★★★

Solid

33

★★

Below

12

★

Weak

Held by 2 funds

Who's Trading

Source dates: Price Oct 9, 2026 · Insiders none · Activists none · Congress none

No recent insider, activist, or congressional trades for SRNE.

Top Holders

Top Holders (2)History

AllNewIncreasedHeldDecreasedExitedFirst report

Checking access…

Fund	Action	Shares	Value	Weight	Est. P&L	Conviction
HUNTINGTON NATIONAL BANK	Unchanged	5,001	$4	0.0%	-99.97%	0
First Command Advisory Services, Inc.	New	569	$0	0.0%	-92.00%	17

SRNESORRENTO THERAPEUTICS INC

1M3M6M1Y3Y5Y

Continue exploring

Smart money flow

Track where institutional capital is flowing

Discover new institutional entries

Fresh positions initiated this quarter

Check sector trends

Capital flows across GICS sectors

Other Healthcare stocks held by institutions

UNHUnitedHealth Group Inc

416 holders · $299.1B

LLYEli Lilly & Co

415 holders · $877.5B

TMOThermo Fisher Scientific Inc

400 holders · $151.4B

JNJJohnson & Johnson

397 holders · $414.1B

DHRDanaher Corp

394 holders · $97.5B

ISRGIntuitive Surgical Inc

393 holders · $111.5B

MRKMerck & Co Inc

390 holders · $230.1B

ABBVAbbVie Inc

385 holders · $302.9B

BSXBoston Scientific Corp

385 holders · $51.8B

ABTAbbott Laboratories

382 holders · $113.8B

High Conviction Moves-Smart Money Convergence-Fund Consensus-Double-Down Detection

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer